Dihexa is an experimental compound claimed to strengthen connections between brain cells and improve learning or memory.
What Dihexa does and why that matters
Dihexa is claimed to help neurons form or strengthen connections. If that happened in people, it could improve learning or memory after injury or cognitive decline. The 2014 paper behind this proposed action was retracted in 2025, so neither the HGF/c-Met mechanism nor the claimed cognitive benefit is established. [1,2]
Function evidence: Memory explanation came from retracted laboratory and animal work
What the cognitive claim would mean
The appeal of Dihexa is the idea that it might make learning easier, improve recall or restore abilities lost after brain injury or cognitive decline. No controlled human trial has shown those changes. More importantly, the foundational paper used to explain how Dihexa might strengthen connections between brain cells was retracted in April 2025. Personal stories or vendor descriptions cannot repair that evidence gap, and the former potency claim should not be used to predict a noticeable cognitive effect. [1,2,3]
What supports this description: No controlled human outcomes; foundational mechanism paper retracted
Dihexa Dosing status
Dose: No consumer dose is established or recommended here. | Frequency: No routine treatment schedule established. | Cycle: No validated consumer cycle. | Route: No routine patient route established.
Preparation: No patient reconstitution recipe. Trial preparation is not a recommendation..
Dihexa is experimental. In April 2025, the journal retracted the 2014 paper behind the HGF/c-Met and cognition claims. That includes the often-repeated line that Dihexa is “10 million times more potent than BDNF.” The retracted paper cannot support those claims. [1,2]
Dihexa Effects
Cognitive benefit. No controlled human outcome trial is established here. The central mechanistic and procognitive paper was retracted, so its findings cannot support a treatment claim. [1,2]
Dihexa Side Effects
Unknown human safety. There is no established human dose, pharmacokinetic profile, or long-term safety evidence. Speculation about c-Met and cancer cannot be converted into a quantified risk or a “safe short cycle.” [2,3]
Frequently Asked Questions About Dihexa
Was the main Dihexa paper retracted?
Yes. The journal published a retraction notice in April 2025 for the 2014 paper that underpinned the HGF/c-Met synaptogenesis narrative. [1,2]
Is there a safe Dihexa dose or cycle?
No human dose or safety-tested cycle is established. A community practice is not clinical evidence. [2,3]
Evidence
Preclinical evidence undermined by a foundational retraction. Dihexa is experimental. In April 2025, the journal retracted the 2014 paper behind the HGF/c-Met and cognition claims. That includes the often-repeated line that Dihexa is “10 million times more potent than BDNF.” The retracted paper cannot support those claims. [1,2]
American Society for Pharmacology and Experimental Therapeutics Retraction: The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the HGF/c-Met system J Pharmacol Exp Ther, 2025. PMID 40312093
Benoist CC, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system (retracted) J Pharmacol Exp Ther, 2014. PMID 25187433
U.S. Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: Dihexa , . Source
Storage
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
